Efficacy of Erzhu Erchen Decoction combined with glimepiride on type 2 diabetes mellitus patients with abdominal obesity

GUO Qianwen; MENG Fanmin; ZHANG Xiaoli

doi:10.3969/j.issn.1002-7386.2025.02.010

Abstract：Objective To observe the efficacy of Erzhu Erchen Decoction combined with glimepiride on type 2 diabetes mellitus(T2DM)patients with abdominal obesity.Methods Seventy-two T2DM patients with abdominal obesity treated in Kunshan Second People's Hospital from May 2022 to January 2024 were selected.They were randomly separated into Western medicine group and combination group using a randomized numerical table method,with 36 cases in each group.Patients in both groups were treated with glimepiride,and those in the combination group were additionally treated with Erzhu Erchen Decoction.The treatment efficacy,traditional Chinese medicine(TCM)syndrome scores,body mass index(BMI),glucose metabolism index,lipid metabolism indicators and adverse events were compared between the two groups.Results The total effective rate was significantly higher in the combination group than that of the Western medicine group(94.44％vs 77.78％,P＜0.05).After treatment,TCM syndrome scores,BMI,visceral fat area,fasting blood glucose(FBG),2h postprandial blood glucose(2hPBG),glycosylated hemoglobin(HbAlc),triglyceride(TG),total cholesterol(TC),and low-density lipoprotein cholesterol(LDL-C)of the two groups were significantly reduced,which were significantly lower in the combination group than the Western medicine group(P＜0.05).The incidence of total adverse events was 13.89％in the Western medicine group and 11.11％in the combination group,showing no significant difference between the groups(P＞0.05).Conclusion Erzhu Erchen Decoction combined with glimepiride for treating T2DM patients with abdominal obesity can produce a high clinical efficacy that effectively improves TCM syndromes,and inhibits the glucose and lipid metabolism with a high safety.